Screener
Summit Therapeutics SMMT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds received related to employee stock purchase plan and exercise of stock options | 3,797 | 2,019 |
| Proceeds from exercise of warrants (3) | — | 5,658 |
| Net cash provided by financing activities | 3,797 | 7,677 |
| Effect of exchange rate changes on cash | (19) | 38 |
| (Decrease) increase in cash, cash equivalents and restricted cash | (118,751) | 106,657 |
| Cash, cash equivalents and restricted cash at beginning of period | 225,582 | 105,187 |
| Cash, cash equivalents and restricted cash at end of period | $106,831 | $211,844 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's financing cash flow?
- Summit Therapeutics (SMMT) reported financing cash flow of $3.8M in Q1 2026.
- How has Summit Therapeutics's financing cash flow changed year-over-year?
- Summit Therapeutics's financing cash flow decreased by 50.5% year-over-year, from $7.68M to $3.8M.
- What is the long-term trend for Summit Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Summit Therapeutics's financing cash flow has grown at a 67.8% compound annual growth rate (CAGR), from $77.92M to $617.53M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Summit Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude